Inhibition of inflammatory response is considered to be an effective treatment strategy for RA, such as targeting TNF, IL-6, CD86/80 or janus kinase (JNK), and is potential to be an effective supplement for disease-modifying antirheumatic drugs (DMARDs) [15–17]. The gene discussed is CD86; the disease is rheumatoid arthritis.